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Background: Although consensus guidelines recommend insulin progression among patients with type 2 diabetes
(T2DM) who fail to meet glycemic targets over time, many fewer patients are progressed than may benefit. We
describe the rationale and design of the MOSAIc (Multinational Observational Study Assessing Insulin use) study, a
multinational observational cohort study to identify patient-, physician, and health care environment-based factors
associated with insulin progression for patients with T2DM in real-world practice.
Methods/design: We will enroll 4,500 patients with T2DM taking initial insulin therapy for ≥3 months across 175
physician practice sites in 18 countries. Extensive demographic, clinical, and psychosocial data at the patient and
physician level and practice site characteristics will be collected at baseline and regular intervals during a 24-month
follow-up period. We will use a multivariable logistic regression model to identify predictors of insulin progression
and highlight potential opportunities for health behavior intervention to improve insulin progression rates.
Secondary outcomes include evaluating factors associated with glycemic control, hypoglycemia, and treatment
adherence among patients who do and do not progress beyond their initial insulin therapy and exploring
geographic heterogeneity in treatment.
Discussion: Practice site and patient recruitment began in 2011 and baseline data will be available in late 2012.
The MOSAIC study’s longitudinal observational design as well as the breadth and depth of data will be used to
explore and quantify predictors of insulin progression and to identify potential opportunities for health behavior
intervention in order to improve T2DM treatment and clinical outcomes.
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Both developed and developing countries face a growing
epidemic of type 2 diabetes (T2DM). Over 3 million (5.2%)
deaths per year are attributable to diabetes [1], making it
the fifth leading cause of death worldwide [2]. The preva-
lence of T2DM is expected to reach 329 million cases
globally by 2030, driven by urbanization, aging of the popu-
lation, and obesity [3]. Treatment and related complications
exact a substantial economic toll [4]. The World Health
Organization estimates that in the period 2006–2015,* Correspondence: jpolinski@partners.org
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reproduction in any medium, provided the orChina will lose $558 billion in foregone national income
due to heart disease, stroke and diabetes [1]. For govern-
ments struggling to maximize citizens’ health with limited
and often dwindling economic resources, T2DM represents
a public health problem of outsized proportions.Need for T2DM treatment intensification over time
Because T2DM is a progressive chronic disease, an
increasingly intensive treatment strategy is needed to
achieve glycemic control. At diagnosis, evidence-based
algorithms recommend dietary and activity modifica-
tions as well as initiation of metformin [5]. When this
treatment strategy, with or without oral anti-diabetic
medications, fails to provide adequate glycemic control,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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insulin therapy, defined as switching from basal insulin
to premixed insulin, adding bolus doses, and/or increas-
ing the frequency of dosing, is recommended when
patients fail to achieve recognized HbA1c targets, which
vary between 6.5%-7.5% [5-7]. The widely-used practice
guidelines detailed in the American Diabetes Association
and the European Association for the Study of Diabetes
consensus statement recommends progression if HbA1c
levels remain ≥7% after 3 months of basal insulin ther-
apy [5]. However, insulin progression does not occur as
often as clinically indicated, with an estimated 75% of
patients on insulin monotherapy not achieving their
HbA1c targets [8]. Another survey of patient records
from academic medical centers found that <50% of eli-
gible patients had therapy progression corresponding to
their diabetes status [9], leaving many patients at risk for
diabetes complications. Clearly, a disconnect between
evidence-based treatment algorithms for insulin progres-
sion and their application in real-world settings exists.
Documented barriers to insulin initiation, but a paucity of
data regarding insulin progression
Most existing research has described barriers to insulin
initiation and adherence. The cross-sectional, multi-
national DAWN (Diabetes Attitudes Wishes and Needs)
study examined patients’ and healthcare professionals’
attitudes regarding insulin initiation [10]. Patient barriers
included: perceived failure in diabetes management; feel-
ings of social stigma and pain; less lifestyle flexibility; in-
jection fears; and erroneous beliefs that insulin is
addictive or toxic [11,12]. Health providers reported a
reluctance to initiate insulin due to the time and effort
burden to teach insulin administration, titrate dosing,
and monitor glucose; perceived risks to patients (weight
gain, hypoglycemia, worsening of comorbid conditions);
and perceived lack of patient adherence to and/or cogni-
tive ability to manage insulin regimens [11,13]. A second
cross-sectional study documented health resource and
environment-related barriers to insulin initiation, includ-
ing lack of insurance and access to insulin products/regi-
mens and primary and auxiliary providers [14]. While
these studies identified important barriers to insulin ini-
tiation, their cross-sectional nature did not allow for an
examination of which barriers meaningfully affected
clinical outcomes, nor did the studies examine barriers
to insulin progression.
Several studies suggest that barriers to insulin progres-
sion may be distinct from those for insulin initiation and
that their effect on clinical outcomes may differ [15-17].
However, their cross-sectional design limits inferences that
can be drawn. There are also few data as to whether treat-
ment guidelines and algorithms for insulin progression are
being followed outside of clinical trials. Finally, little isknown about patients’ outcomes in routine clinical prac-
tice preceding or following insulin progression. Longitu-
dinal, observational studies in real-world settings are
needed to identify barriers to insulin progression as well
as to quantitatively assess the association between lack of
progression and T2DM outcomes.
Objective
The MOSAIc (Multinational Observational Study Asses-
sing Insulin use: understanding the challenges associated
with progression of therapy) study is a multi-national,
non-interventional, prospective observational cohort
study. Using the Anderson model of health behavior
[14,15] framework, the primary objective of MOSAIc is to
identify patient, physician, and health care environment
factors that influence insulin progression among patients
with T2DM and to quantify the relationships between
these factors and long-term clinical outcomes. Additional
objectives include the evaluation of factors associated with
optimal glycemic control, hypoglycemia, and treatment
adherence among patients with T2DM who do and do not
progress beyond their initial insulin therapy. MOSAIc will
also explore geographic heterogeneity with respect to
T2DM treatment, insulin delivery modality (pen, syringe,
pump), insulin progression, and glycemic control, includ-
ing the challenges of insulin use among patients who prac-
tice fasting for religious and/or cultural reasons [16]. We
will examine patient-physician communication regarding
diabetes treatment, patients’ diabetes knowledge and self-
care behaviors and their impact on glycemic control, and
patients’ health-related quality of life as predicted by
T2DM knowledge, attitudes, behaviors, and treatment.
Comparisons among insulin regimens and their associ-
ation with cardiovascular health outcomes, hypoglycemia,
health care utilization and costs will also be studied. Sec-
ondary research objectives are summarized in Table 1.
Methods/design
A total of 175 physician practice sites across 18 coun-
tries (Abu Dhabi, Argentina, Brazil, Canada, China, Ger-
many, India, Israel, Italy, Japan, Mexico, Russia, Saudi
Arabia, South Korea, Spain, Turkey, United Kingdom,
United States including Puerto Rico) will be invited to
participate (Table 2). Participating countries were chosen
based on geographic region, population aged 20–79, and
the T2DM prevalence in each region and country [17].
We will recruit two types of sites, those where physi-
cians practice primary care, internal or general medicine
(general medicine sites), and those where physicians
practice endocrinology or diabetology (specialty sites).
The recruitment goal for each site type reflects the
country-specific prevalence of each practice type [18,19]
as well as country-specific approaches to T2DM insulin
treatment; in some countries, primary care providers
Table 1 Proposed secondary research objectives




• Diabetes-related health care utilization
• Diabetes-related health costs
Geographic heterogeneity in:
• Insulin progression rates
• Insulin treatment modality (pen, syringe, pump)
• Glycemic control
• Patterns of T2DM treatment
Challenges associated with insulin use:
• Fasting for religious/cultural reasons
• Health-related quality of life
• Diabetes self-care
• Diabetes knowledge







Impact of insulin progression on:
• Cardiovascular outcomes
• Hypoglycemia
• Health-related quality of life
• Diabetes distress
• Diabetes self-care
• Health care resource utilization
• Health care costs
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is the purview of specialists [20,21]. Both types of sites
are approached for participation based on previous re-
search experience with the contract research organization
performing recruitment (Quintiles) and/or with Lilly and
treatment of at least 4 patients with T2DM per day.
Efforts will be made to vary both practice location
(urban/rural) and size and type of practice (academic/
stand-alone). Using this purposive sampling strategy, our
goal is to recruit a heterogeneous population of patients
with T2DM using insulin that reflects the underlying
population with T2DM in each participating country.
Each practice site receives remuneration for the burden
associated with data collection and entry. There is no re-
muneration or incentive for the number of patientsenrolled or for the number of patients progressed. At
present, practice sites are being actively recruited in 13 of
18 countries, with recruitment efforts planned in the
remaining 5 countries in summer 2012. The practice site
recruitment rate varies between 25% (Japan and China)
and 40% (e.g., U.S., Mexico, Saudi Arabia) at present, with
the primary reasons for non-participation being conduct
of competing studies, lack of interest in observational re-
search, lack of personnel, perception that remuneration
for observational research is too low, and concerns
regarding the number of questionnaires. A total of 125
sites are recruiting patients at this time.
At each study site, patients with T2DM who present
during the normal course of care and who meet four cri-
teria will be invited to enroll: 1) age ≥18; 2) taking any
commercially-available insulin therapy other than inten-
sive basal-bolus insulin therapy (i.e., basal + 3 prandial
injections) from any manufacturer for ≥3 months with
or without any combination of approved non-insulin
anti-diabetic medications; 3) are not simultaneously par-
ticipating in a study that includes an investigational drug
or procedure; and 4) are proficient in the country’s pri-
mary language such that they will be able to complete
self-report questionnaires. Based on sample size calcula-
tions described below, we will enroll 4,500 patients
across all sites. The study has received ethics approval in
all 18 countries. All patients will complete informed
consent forms approved by their country-specific institu-
tional review boards (Additional file 1). The study’s ana-
lytic plan has been approved by the Brigham and
Women’s Hospital Institutional Review Board.
Study design and data collection
Upon enrollment, patients’ naturalistic diabetes care and
outcomes will be followed prospectively for 24 months.
There are no additional treatments, visits, or laboratory
collections required beyond those occurring within the
course of normal care. A patient may discontinue study
participation at any time. Data collection occurs during an
initial baseline visit and during four subsequent prospect-
ive visit windows (within ±3 months) at 6, 12, 18, and
24 months. Baseline clinical information will be assessed
retrospectively from the medical record and includes
T2DM diagnosis date, treatment and complications, and
T2DM medication history. Diabetes-related health care re-
source utilization (physician visits, hospitalizations, and
auxiliary provider visits: diabetes educators, ophthalmolo-
gists, podiatrists, cardiologists, dietitians, and nephrolo-
gists), most recent recorded laboratory and vital sign
values, and other comorbidities will be assessed at the
baseline visit for the period 6 months prior and again at
subsequent visits for the period between visits. Other non-
anti-diabetic, concurrent medications and demographics
will be assessed at the baseline visit. Extensive information




















8.1% China 968,975 9.0% 11 2 9
India 737,003 9.2% 26 10 16
Japan 95,341 7.9% 7 4 3
South Korea 36,204 7.7% 6 4 2
50 20 30
Europe 10% Germany 62,810 5.5% 8 2 6
Italy 45,637 5.3% 6 1 5
Russia 109,167 10.0% 12 10 2
Spain 34,896 6.5% 6 1 5
United
Kingdom




12.1% Canada 25,141 8.7% 6 1 5
United States 216,805 9.6% 30 6 24




10.8% Abu Dhabi 6,107 19.2% 6 9 31
Israel 4,708 7.6% 6 1 5
Saudi Arabia 17,023 20.0% 6 3 3




7.8% Argentina 26,265 5.7% 6 5 1
Brazil 127,995 10.4% 6 1 5
Mexico 69,324 15.9% 6 2 4
18 8 10
Totals 175 59 116
*Age standardized. Obtained from the International Diabetes Federation Diabetes Atlas [17].
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tudes, and behaviors; hypoglycemia and fasting; general
health behaviors; patient-provider relationships; and per-
ceived physical and psychological well-being and social
status will be collected during visits using validated self-
report questionnaires developed for patients with a 6th
grade literacy level (Table 3). Patients who have difficulty
completing questionnaires may receive assistance as long
as responses are their own. Many of the questionnaires
are part of the ENSEMBLE MDS, a 68-item battery of
instruments designed to explore treatment response het-
erogeneity regardless of disease state [22]. For example,
the ENSEMBLE MDS includes the EQ-5D, which measure
general quality of life [23]. Other questionnaires are
diabetes- or insulin-specific [25-29]. The full battery of
questionnaires takes an average 35–40 minutes to
complete. Patients do not receive remuneration for study
enrollment nor for questionnaire completion.Because physicians also play an important role in insu-
lin progression, each physician will complete self-report
questionnaires regarding his/her demographics and
overall T2DM treatment beliefs and prescribing prefer-
ences, including type of device/delivery mechanism,
options for titration, side effects, complexity of patient
training and education, cost of therapy, availability of
education materials, patient-specific factors such as age,
education, and cultural considerations, and consider-
ation of accepted treatment guidelines. No data will be
collected about specific products or brands. The phys-
ician will also indicate his/her treatment and HbA1c
goals for each enrolled patient at the baseline visit. Prac-
tice site characteristics (academic/non-academic, rural/
urban, practice size, time dedicated to diabetes, and
practice type [general medicine site/specialty site]) that
may influence diabetes treatment practices will be
enumerated as well.







Any visit at which a
patient is progressed
Any visit at which a patient
discontinues the study
Diabetes- and insulin-related knowledge, attitudes, and behaviors
Blood glucose monitoring practices X
Brief Diabetes Knowledge Test [25] X X X
Diabetes Distress Scale [26] X X X X
Experience with Insulin Therapy Questionnaire [27] X X X
Hypoglycemia and Fasting Survey (designed by the
study team)
X X X X
Insulin Cost Questionnaire (designed by the study
team)
X X X X X
Insulin Specific Adherence Questionnaire (designed
by the study team)
X X X X X
Summary of Diabetes Self-Care Activities [28] X X X X
Health status profile (all components part of ENSEMBLE MDS) [22]
Depression diagnosis question X X
Barratt Simplified Measure of Social Status Education
question
X X
Barratt Simplified Measure of Social Status
Occupational Status question
X X
MacArthur Income Questionnaire X X
Perceived Social Support Scale X X
Perceived Stress Scale X X
Psychological Health Questionnaire X X
Self-reported health questions (EQ-5D) [23] X X
Total Illness Burden Index X
Subjective Social Economic Status X
General health behaviors
Smoking and alcohol use X
Participation in physical exercise X
Health care access, patient-provider relationship
Insurance to pay for prescription medications
question
X
Interpersonal Processes of Care Survey [29] X X X
Physician: treatment preferences and goals
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Practice site personnel will enter and submit patients’
clinical data electronically to a secure virtual data center.
Electronic data entry forms feature automated quality
checks to ensure that values are within range and meet
quality standards. Self-reported data will be gathered
using paper-and-pencil forms which are mailed to Quin-
tiles for data entry into a database program featuring
similar quality control.
Primary outcome: insulin progression
Insulin progression is defined based on each patient’s in-
sulin therapy regimen at the baseline visit (Table 4). If a
patient begins the study on basal insulin, with or withoutany other non-insulin anti-diabetic medication, progres-
sion will be defined as the addition of prandial insulin,
an increased frequency of insulin injections, change to
an insulin mixture, or addition of a glucagon-like pep-
tide 1 (GLP) medication or ≥1 oral anti-diabetic (OAD)
medications. Alternatively, if a patient begins the study
on an insulin regimen of basal insulin plus <3 prandial
injections daily or is using insulin mixtures (both regi-
mens may be used alone or with other non-insulin anti-
diabetic medications), then progression is defined as an
increased frequency of insulin injections, change to a
basal-bolus regimen, or addition of a GLP-1 or ≥1 OAD
medications. Importantly, this definition allows for the
inclusion of T2DM patients who may be using insulin
Table 4 Outcome definitions for insulin progression, based on initial insulin therapy
Initial Insulin Therapy Definition of Insulin Progressiona,b
Basal alone or in combination with any approved
non-insulin anti-diabetic medications
Addition of prandial insulin (≥1 injection: basal plus or basal-bolus)
Additional injections
- QD to BID administration of NPH
- Insulin glargine[Lantus]/Insulin levemir[Determir]
- ILPS or insulin mixtures
- Intermediate-acting NPH
Mixtures
- human/animal/analog premixed insulin (combination of short-
and long-acting insulin in the same formulation)
Addition of a GLP-1
Addition of oral medications
Basal Insulin plus additional insulin therapy (less than
a full basal-bolus regimen (basal + <3 prandial injections))
or in combination with any approved non-insulin
anti-diabetic medications
Additional insulin injections (e.g., 1 to 2 injections, or 2 to 3 injections)
Basal-bolus regimen
Addition of a GLP-1
Addition of oral medications
Insulin mixtures alone or in combination with any
approved non-insulin anti-diabetic medications
Additional insulin injections (e.g., 1 to 2 injections, or 2 to 3 injections)
Basal-bolus regimen
Addition of a GLP-1
Addition of oral medications
Abbreviations: BID= twice a day; GLP-1=glucagon-like peptide 1; ILPS= insulin lispro protamine suspension; NPH=neutral protamine Hagedorn; QD= every day.
aReferrals to a specialist (eg, endocrinologist) for progression of therapy will be captured.
bFor the purpose of this study, progression will be defined as the first progression from initial therapy (as defined above).
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with T2DM. As MOSAIc will investigate the care
patients receive in real-world settings, it is important to
capture the spectrum of employed treatment strategies,
even when these strategies may not reflect current estab-
lished treatment guidelines. The progression date is the
first visit date at which a patient is progressed or is re-
ferred to another health care provider for progression, as
recorded in the medical record.
Statistical analysis
Multivariable regression modeling of the binary response
variable (progressed/not progressed) will be conducted
using a logistic main-effects regression model to exam-
ine the association between insulin progression and pa-
tient-, physician-, and healthcare environment-based
factors. A generalized estimating equation (GEE) [24]
will be used to estimate the parameters of the model
and will take into account the clustering of patients
within physicians and of physicians within clinical prac-
tice sites. Fifty risk factors assessed at baseline (Table 5)
will be included as independent variables and will be
evaluated for association with progression using False
Discovery Rate p-values to maintain the type I error at
0.05 across the entire analysis. The 50 risk factors were
selected based on expert subject matter knowledge and
literature reviews conducted by the research team.Multiple imputation using Monte Carlo Markov Chain
will be used in the modeling to address any missing data.
Goodness-of-fit for the model will be examined using re-
ceiver operating characteristic analysis and the Hosmer-
Lemeshow test.
Sample size considerations
The sample size calculation was based on the inclusion
of 50 independent variables in the primary multivariate
regression model and 90% power to identify a predictor
that impacts the likelihood of progression from 20% to
25% at a 0.001 level of significance (a type I error rate of
0.05 divided by 50 in a Bonferroni manner). We
assumed a correlation of 0.5 among predictors. We esti-
mate that 20% of patients will progress during the study
and 20% will be lost to follow-up over the 24 month
study period. Given these assumptions, 4,500 patients
are needed to identify a predictor that impacts the likeli-
hood of progression with a 5% change (from 20% to
25%) for a 1 standard deviation increase in the variable.
Discussion
Safety reporting
As MOSAIc is an observational study, there are no pro-
visions for a data safety and monitoring board. Practice
sites and physicians will continue to follow all applicable
laws, regulations, and practices in their respective
Table 5 The 50 patient-, provider-, and health









6 Duration of type II diabetes
7 Body mass index (BMI)*
8 Hemoglobin A1c (HbA1c)*
9 Low-density lipoprotein (LDL)*
10 High-density lipoprotein (HDL)*
11 Urine microalbumin to serum creatinine ratio*
12 Systolic blood pressure*
13 Number of days blood sugar was tested in the past week*
14 Daily units basal or intermediate insulin*
15 Daily units short-acting (regular) insulin*
Patient medication history
16 Metformin use †
17 Use of a sulfonurea †
18 Use of a glitazone †
19 Use of another oral antidiabetic drug †
20 Use of an ACE inhibitor {
21 Use of an ARB {
22 Use of a thiazide {






Patient self-care/healthy behavior measures at the baseline visit €
28 Insulin-specific Adherence Questionnaire summary score
29 Current Fasting Practices
30 Current smoking use (any smoking during past 7 days)
31 Current Alcohol Use
32 Number of days on which patient exercised during the last 7 days
33 Insurance to pay for drugs
Patient health care resource utilization in the 6 months prior to
the baseline visit €
34 Number of hospitalizations due to diabetes, including MI and ESRD
35 Number of diabetes-related visits to physician who treats patient’s
diabetes
36 Number of visits to an auxiliary diabetes provider
Table 5 The 50 patient-, provider-, and health
environment-specific variables included in the insulin





39 Practice affiliation (Academic versus non-academic)
40 Practice location (Urban versus rural)
41 Practice time dedicated to diabetes (patients/month)
42 Practice size
43 Practice type (primary care/internal medicine versus diabetologist/
endocrinologist)
44 Prescribing choices and preferences Score
Potentially Modifiable Variables
45 Patient Relationship with Health Care Provider €
46 Physician’s target HbA1c level for this patient £
47 Experience with Insulin Treatment Questionnaire Score €
48 Diabetes Self Care Activities Survey Score €
49 Diabetes Knowledge Test Score €
50 Diabetes Distress Scale Score €
a Definition includes presence of any of: transient ischemic attack, stroke,
congestive heart failure, arrhythmia, coronary artery disease, myocardial
infarction, peripheral arterial occlusive disease.
b Definition includes presence of any of: retinopathy, nephropathy,
neuropathy, hyperlipidemia, diabetic coma, hyperglycemic hypermolar
nonketototic syndrome, amputation, arthritis, cancer/malignancy, depression,
gastroparesis, diabetic foot, other skin infections, and oral infections,
pyelonephritis, pneumonia, erectile dysfunction.
* Most recent values within the 6 months prior to the baseline visit, as
recorded in the patient’s medical record.
† Ever use or concomitant use at the day prior to the baseline visit, either
from self-report or the patient’s medical record.
{ Concurrent use reported at the baseline visit via self-report or the patient’s
medical record.
} Determined via self-report at the baseline visit or from the patient’s medical
record.
€ Via patient self-report at the baseline visit.R
Via physician self-report at the practice site enrollment.
£ Via physician self-report at the patient’s baseline visit.
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events related to any anti-diabetic treatments, such as
reporting events to government regulators and/or the
local market authorization holder.
Limitations
There are several important limitations to the proposed
observational study. Simply observing and recording
T2DM treatment patterns over the course of 24 months
might produce a Hawthorne effect that influences pa-
tient and physician behaviors regarding insulin progres-
sion. In an attempt to quantify this effect, we measure
patterns of T2DM treatment and care in the 6 months
prior to the study so that a historical baseline is avail-
able. We only have access to a patient’s medical records
as maintained by the physician who treats the patient’s
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tient sees other health care providers, the full extent of
her comorbidities and prescription drug use may not be
captured. However, patients will be able to self-report
comorbidities and prescription drug use at their baseline
visit, mitigating the loss of some information. Second,
some treating physicians will refer their patients to an-
other physician, often an endocrinologist or diabetolo-
gist, for the purposes of insulin progression and will
note this on study forms. If these patients do not return
to their original provider, the true progression status of
these patients will be unknown. For the purposes of our
analyses, we will include these patients and count them
as meeting the definition of insulin progression, similar
to an “Intention-to-Treat” analysis because the referring
physician intended for the patient to be progressed. If
these patients are not actually progressed by the new
physician, this strategy will result in misclassification of
their outcome. This approach may result in some bias in
the parameter estimates, but we believe our strategy is
conservative, more appropriate and potentially less
biased than deleting these patients from the analyses. Fi-
nally, given sample size limitations and practicality, we
consider 50 potential predictors of insulin progression in
our primary prediction model. Additional predictors of
progression might be identified and may be explored in
sensitivity analyses.Funding and responsibilities
This study is funded by Eli Lilly and Company, Study
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The MOSAIc study is a multinational longitudinal ob-
servational cohort study among patients with T2DM
that will specifically examine factors associated with in-
sulin progression in real-world clinical practice. Exten-
sive patient demographic, clinical, and psychosocial data
as well as physician-specific and health care environ-
ment/practice-site data will be collected. The research
team will capitalize on the breadth and depth of these
data to explore and quantify predictors of insulin pro-
gression and to identify potential opportunities for
health behavior intervention in order to improve T2DM
treatment and clinical outcomes.Additional file
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